1.Piazza G and Goldhaber SZ. Physician alerts to prevent venous thromboembolism. J Thromb Thrombolysis 2010;30: 1-6.

2.Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006; 25: 101-161.

3.Guyatt GH, Akl EA, Crowther M, Gutterman DD and Schuunemann HJ. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 7s-47s.

4.Shackford SR, Rogers FB, Terrien CM, Bouchard P, Ratliff J and Zubis R. A 10-year analysis of venous thromboembolism on the surgical service: the effect of practice guidelines for prophylaxis. Surgery 2008; 144:3-11.

5.Wang L, Gong Z, Jiang J, Xu W, Duan Q, Liu J and Qin C. Confusion of wide thrombolytic time window for acute pulmonary embolism: mass spectrographic analysis for thrombus proteins. Am J Respir Crit Care Med 2011; 184:145-146.

6.Giancotti FG and Ruoslahti E. Integrin signaling. Science 1999; 285: 1028-1032.

7.Humphries MJ. Integrin structure. Biochem Soc Trans 2000; 28: 311-339.

8.Takada Y, Ye X and Simon S. The integrins. Genome Biol 2007; 8: 215.

9.Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, Joachimiak A, Goodman SL and Arnaout MA. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science 2001; 294: 339-345.

10.Solovjov DA, Pluskota E and Plow EF. Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J Biol Chem 2005; 280: 1336-1345.

11.Gerber DJ, Pereira P, Huang SY, Pelletier C and Tonegawa S. Expression of alpha v and beta 3 integrin chains on murine lymphocytes. Proc Natl Acad Sci U S A 1996; 93: 14698-14703.

12.Litynska A, Przybylo M, Ksiazek D and Laidler P. Differences of alpha3beta1 integrin glycans from different human bladder cell lines. Acta Biochim Pol 2000; 47: 427-434.

13.Wang LM, Duan QL, Yang F, Yi XH, Zeng Y, Tian HY, Lv W and Jin Y. Activation of circulated immune cells and inf l ammatory immune adherence are involved in the whole process of acute venous thrombosis. Int J Clin Exp Med 2014; 7: 566-572.

14.Wang LM, Duan QL, Yi XH, Zeng Y, Gong Z and Yang F. Venous thromboembolism is a product in proliferation of cancer cells. Int J Clin Exp Med 2014; 7: 1319-1323.

15.Wang L, Gong Z, Liang A, Xie Y, Liu SL, Yu Z, Wang L and Wang Y. Compromised T-cell immunity and virus-like structure in a patient with pulmonary hypertension. Am J Respir Crit Care Med 2010; 182: 434-435.

16.Wang LM, Zhang XY, Duan QL, Lv W, Gong Z, Xie Y, Liang AB and Wang Y. Rod-like bacteria and recurrent venous thromboembolism. Am J Respir Crit Care Med 2012; 186: 696.

17.Wang H, Duan Q, Wang L, Gong Z, Liang A, Wang Q, Song H, Yang F and Song Y. Analysis on the pathogenesis of symptomatic pulmonary embolism with human genomics. Int J Med Sci 2012; 9: 380-386.

18.Gong Z, Liang AB, Wang LM, et al. The expression andsignificance of immunity associated genes mRNA in patients withpulmonary embolism [in Chinese]. Zhonghua Nei Ke Za Zhi 2009;48:666-669.

19.Lv W, Wang L, Duan Q, Gong Z, Yang F, Song H and Song Y. Characteristics of the complement system gene expression def i ciency in patients with symptomatic pulmonary embolism. Thromb Res 2013; 132: e54-57.

20.Lv W, Duan Q, Wang L, Gong Z, Yang F and Song Y. Gene expression levels of cytokines in peripheral blood mononuclear cells from patients with pulmonary embolism. Mol Med Rep 2013; 7: 1245-1250.

21.Duan Q, Lv W, Wang L, Gong Z, Wang Q, Song H and Wang H. mRNA expression of interleukins and Th1/Th2 imbalance in patients with pulmonary embolism. Mol Med Rep 2013; 7: 332-336.

22.Xie Y, Duan Q, Wang L, Gong Z, Wang Q, Song H and Wang H. Genomic characteristics of adhesion molecules in patients with symptomatic pulmonary embolism. Mol Med Rep 2012; 6: 585-590.

23.Lv W, Duan Q, Wang L, Gong Z, Yang F and Song Y. Expression of B-cell-associated genes in peripheral blood mononuclear cells of patients with symptomatic pulmonary embolism. Mol Med Rep 2015; 11: 2299-2305.

24.Qianglin Duan,Wei Lv, Minjun Yang, Fan Yang, Yongqiang Zhu, Hui Kang, Haoming Song, Shengyue Wang,Lemin Wang, Hui Dong Characterization of immune cells and perforin mutations in a family with venous thromboembolism Int J Clin Exp Med 2015;8(5):7951-7957.

25.Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R and Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006; 367: 1075-1079.

26.Clayton TC, Gaskin M and Meade TW. Recent respiratory infection and risk of venous thromboembolism: casecontrol study through a general practice database. Int J Epidemiol 2011; 40: 819-827.

27.Schmidt M, Horvath-Puho E, Thomsen RW, Smeeth L and Sorensen HT. Acute infections and venous thromboembolism. J Intern Med 2012; 271: 608-618.

28.Yi XH, Wang LM, Liang AB, Gong Z, Lai RQ, Zhu XY, Rui WW and Wang YN. Severe acute respiratory syndrome and venous thromboembolism in multiple organs. Am J Respir Crit Care Med 2010; 182: 436-437.

29.Wang L, Song H, Gong Z, Duan Q and Liang A. Acute pulmonary embolism and dysfunction of CD ₃ CD ₈ T cell immunity. Am J Respir Crit Care Med 2011; 184: 1315.

30.Song HM, Wang LM, Gong Z, Liang AB, Xie Y, Lv W, Jiang JF, Xu WJ and Shen YQ. T cell-mediated immune def i ciency or compromise in patients with CTEPH. Am J Respir Crit Care Med 2011; 183: 417-418.

31.Duan Q, Gong Z, Song H, Wang L, Yang F, Lv W and Song Y. Symptomatic venous thromboembolism is a disease related to infection and immune dysfunction. Int J Med Sci 2012; 9: 453-461.

32.Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Archives of Internal Medicine 2006;166:458-64.

33.Khorana AA, Liebman HA, White RH, Wun T and Lyman GH. The risk of venous thromboembolism in patients with cancer. Ame Society of Clin Oncol Educ Book 2008; 240-248.

34.Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. Journal of Clinical Oncology 2007;25:70-6.

35.Wun T and White RH. Epidemiology of cancer-related venous thromboembolism. Best Prac Res Clin Haematol 2009; 22: 9-23.

36.Blom JW, Doggen CJ, Osanto S and Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. Jama 2005; 293: 715-722.

37.Le-Min Wang, Qiang-Lin Duan, Xiang-Hua Yi, Yu Zeng, Zhu Gong, Fan Yang. Venous thromboembolism is a product in proliferation of cancer cells. Int J Clin Exp Med 2014; 7: 1319-1323.

38.Duan Q, Wang L, Yang F, Li J, SongY, Gong Z, Li G, Song H, Zhang X, Shen Z, Dart A. Internal relationship between symptomatic venous thromboembolism and risk factors: up-regulation of integrin β1, β2 and β3 levels. Am J Transl Res 2015; 7(3):624-631.

39.Song Y, Yang F, Wang L, Duan Q, Jin Y and Gong Z. Increased expressions of integrin subunit beta1, beta2 and beta3 in patients with venous thromboembolism: new markers for venous thromboembolism. Int J Clin Exp Med 2014; 7: 2578-2584.